Techable Spółka z Ograniczoną Odpowiedzialnością (KRS 0001021112, NIP 8952253675) is a Polish company, headquartered in Wrocław, Dolnośląskie voivodeship. Techable operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since February 22, 2023. Techable's most recently reported net revenue was 2.4 K PLN for 2025.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - Techable
Identity
- Name
- Techable Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- Limited Liability Company (LLC)
- Founded
- February 22, 2023
- Registry status as of
- July 3, 2026
- Latest entry
- July 3, 2026
- Founding act
- 16.02.2023
Articles of association history (3)
- February 16, 2023: 16.02.2023
- August 25, 2023: 25.08.2023 R. REP A NUMER 2724/2023 NOTARIUSZ ADAM BILIŃSKI KANCELARIA NOTARIALNA WE WROCŁAWIU UL. ŚWIĘTEGO ANTONIEGO 26 UCHYLENIE DOTYCHCZASOWEGO TEKSTU UMOWY SPÓŁKI I NADANIE UMOWIE SPÓŁKI NOWEGO BRZMIENIA
- February 4, 2026: 2.04.2026 R., NOTARIUSZ ADAM BILIŃSKI, KANCELARIA NOTARIALNA WE WROCŁAWIU, REP. A NR 1046/2026, ZMIANA PAR. 4, PAR. 5, PAR. 6 UMOWY SPÓŁKI
Activities
Other activities
Address and contact
- Address
- UL. BIERUTOWSKA, 57-59, 51-317, WROCŁAW, POLSKA
- Voivodeship
- DOLNOŚLĄSKIE
- District
- WROCŁAW
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-72058-89239-JUBVI-20
Risk and payment profile - Techable
Credibility rating
61.5 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
Spółka wykazuje sygnały niestabilności organizacyjnej: częste zmiany w zarządzie. Może to wskazywać na podwyższone ryzyko współpracy.
Shareholder changes
1
1/3 yrs
Board changes
3
3/3 yrs
PKD changes
1
1/3 yrs
Name changes
0
0/3 yrs
Data from 3 years of registry activity.
Credibility history
Payment reliability score from 2023–2025
Current: C (62/100)
Trend: improving (+3.7 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2023–2025
Current: 104 PLN
Safe: 46.8 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Techable
Founded
February 22, 2023
3 years in operation
Legal form
Limited Liability Company (LLC)
Registry: RejP
Headquarters
WROCŁAW
DOLNOŚLĄSKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
8.8 K PLN
162 shares total
Shareholders
3
shareholders
Board
1 person
Proxies: 1
Filed years
3 years
2023–2025 · profitable: 1/3
Registry entries
14
latest: July 3, 2026
Revenue
2.4 K PLN
2025
Net profit
70.35 PLN
2025
Assets
5.1 K PLN
2025
Equity
5.0 K PLN
2025
Valuation
2.5 K PLN
Medium confidence
Board and connected people - Techable
People holding roles at Techable according to the Polish National Court Register. Follow a name for that person's full profile and their other companies.
- Jaromir KawęckiPresident of the board
- Marcin Lech WielebskiPresident of the board, Majority shareholder, Commercial proxy
- Paweł Piotr ModrzyńskiBoard member, Majority shareholder, Commercial proxy
Directories and rankings for this location
Public procurement
Trademarks
Reviews
Rate business credibility - Techable.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.